News2 – Page 2 – Verséa
 

News2

Verséa™ Ophthalmics – proud sponsor of 2022 CEDARS/ASPENS Annual Meeting

Verséa Ophthalmics is a proud sponsor of this year’s 2022 CEDARS/ASPENS Annual Meeting, taking place today and tomorrow at JW Marriott Camelback, Scottsdale (AZ). CEDARS/ASPENS is a not-for-profit society whose mission is to expand the knowledge of ophthalmic surgery and foster excellence in patient care through clinical experience, peer-to-peer exchange, and practice education. Their mission...

Verséa™ Ophthalmics featured at the Eyes On 2023 Corporate Exhibit Hall Interview series

As part of the corporate exhibit hall interview series at the Eyes On 2023, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Brittany J. McMurren, OD. During the interview, titled “A Deep Dive into New Testing & Therapeutic Innovations”  Rob Sambursky, MD presented new testing and therapeutic innovations that Verséa Ophthalmics is bringing to...

Verséa™ Ophthalmics President, Dr. Rob Sambursky, interviewed by Ophthalmology Times

Following the American Academy of Ophthalmology (AAO) 2022 Annual Meeting held in Chicago, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Ophthalmology Times to provide an overview of the company and its products. Dr. Sambursky spoke about BIOVANCE 3L Ocular, a 3-layered decellularized, dehydrated human amniotic membrane (DDhAM) designed for comfort and improved handleability,...

Verséa™ Ophthalmics is presenting at the American Academy of Optometry (AAOpt) Meeting 2022

This week Verséa Ophthalmics team is presenting at the American Academy of Optometry AAOpt 2022 Meeting in San Diego (CA). Visit our booth # 405, where we will be demonstrating our new Tear-Based Point of Care (T-POC) Quantitative Testing Platform that consists of a portable, multifunctional reader and two tear-based quantitative biomarker test kits: –...

Verséa Holdings, Inc. Launching Verséa AgroTech and its proprietary Extended Shelf-life Packaging System at the IFPA Global Produce & Floral Show

At the upcoming International Fresh Produce Association (IFPA) Global Produce & Floral Show taking place in Orlando (FL) from October 27th to 29th 2022,  Verséa Holdings, Inc. is officially launching a new business division Verséa AgroTech and its proprietary next-generation Extended Shelf-life Packaging (ESP) System. Dr Perry D. Lidster, Ph.D., the Chief Scientific Officer of...

Verséa Holdings, Inc. is Launching Verséa Health and Verséa Easy Lab™ at the NACS Show 2022

At this year’s NACS Show 2022 Verséa Holdings, Inc. is launching their new business division Verséa Health and their Product Line Portfolio Verséa Easy Lab™. James Olin, Chief Commercial Officer at Verséa, explains the reason behind the launch: “Verséa Health was created with a mission to give millions of Americans direct-access to the most essential...

Verséa™ Ophthalmics is Launching Novel, Point-of-Care, Tear-Based Diagnostic Test Platform at the AAO 2022

New innovative, rapid, tear-based, POC diagnostic test platform is designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders   At this year’s Expo of the American Academy of Ophthalmology AAO 2022 – booth # 1251, Verséa Ophthalmics is launching their comprehensive Product Portfolio and demonstrating...

Verséa Searching For Brightest Students and Recent Graduates at the University of Tampa to Join Paid Internship Program

Verséa is looking for this year’s brightest students and recent graduates to join our Paid Internship Program! Today we are at the University of Tampa searching for ambitious individuals who wish to gain professional experience in Marketing & Business Development at one of the fastest-growing healthcare companies in the U.S. CONTACT US TODAY at 1.813.345.2185...

Verséa™ Ophthalmics Signs Exclusive Global Commercialization Agreement With AXIM® Biotechnologies for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

“With exclusive global licensing rights to AXIM’s Eye Diagnostics portfolio, Verséa will be introducing a new innovative, rapid, tear-based, POC lab-testing platform designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.”   Verséa Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), signed exclusive...